Supports Irish researchers in transnational collaborative pre-clinical therapy studies on rare diseases using small molecules and biologicals. Projects should focus on novel therapies, predictive biomarkers, replication of studies, and proof of concept for clinical trial readiness. Funding covers personnel, running costs, PPI, equipment, data management, dissemination, and sub-contracting. Excludes ATMP therapies, new model development, clinical trials, and certain disease areas. Projects last up to 36 months starting in 2026.
Open to transnational consortia excluding Host Institutions in Northern Ireland. Irish partners cannot receive funding for basic biomedical research, stem cell procurement, or projects linked to tobacco or alcohol industry. Projects must focus on rare diseases per European definition and exclude spe
